We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Purpose of This Study is to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02985879
Recruitment Status : Recruiting
First Posted : December 7, 2016
Last Update Posted : March 7, 2018
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

Condition or disease Intervention/treatment Phase
Progressive Supranuclear Palsy Drug: Placebo Drug: ABBV-8E12 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 330 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
Actual Study Start Date : December 16, 2016
Estimated Primary Completion Date : June 11, 2020
Estimated Study Completion Date : June 11, 2020

Arm Intervention/treatment
Placebo Comparator: Group 3
Placebo for ABBV-8E12
Drug: Placebo
placebo solution for IV infusion
Experimental: Group 1
Dose 1 ABBV-8E12
Drug: ABBV-8E12
ABBV-8E12 (20 mg/mL) solution for IV infusion
Experimental: Group 2
Dose 2 ABBV-8E12
Drug: ABBV-8E12
ABBV-8E12 (20 mg/mL) solution for IV infusion

Primary Outcome Measures :
  1. Change from Baseline to Week 52 in Progressive Supranuclear Palsy Rating Scale (PSPRS) Total Score [ Time Frame: Baseline, Week 52 ]
    The PSPRS is a 28-item scale comprising 6 domains (daily activities, mentation, bulbar, ocular motor, limb motor, and gait/midline).

  2. Adverse Events [ Time Frame: 52 weeks ]

Secondary Outcome Measures :
  1. Time to Cmax (Tmax) for ABBV-8E12 [ Time Frame: 16 weeks ]
  2. Change from Baseline to Week 52 in Clinical Global Impression of Change (CGI-C) [ Time Frame: Baseline, Week 52 ]
    The CGI-C is a clinician's rating of improvement in disease severity.

  3. Midbrain Atrophy As Measured by Volumetric Magnetic Resonance Imaging (MRI) [ Time Frame: Baseline, Week 52 ]
    Midbrain atrophy as measured by change in volumetric MRI from baseline to Week 52.

  4. Area under the concentration time curve (AUC) for ABBV-8E12 [ Time Frame: 16 weeks ]
  5. Maximum observed serum concentration (Cmax) for ABBV-8E12 [ Time Frame: 16 weeks ]
  6. Serum concentration at the end of a dose interval (Ctrough) for ABBV-8E12 [ Time Frame: 52 weeks ]
  7. Change from Baseline to Week 52 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) [ Time Frame: Baseline, Week 52 ]
    The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease.

  8. Change from Baseline to Week 52 in Schwab and England Activities of Daily Living Scale (SEADL) [ Time Frame: Baseline, Week 52 ]
    The SEADL assesses the subject's ability to perform daily activities.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subject with age 40 years or greater at the time of signed consent.
  • Meets the criteria for possible or probable progressive supranuclear palsy (Steele-Richardson-Olszewski Syndrome).
  • Presence of PSP symptoms for less than 5 years.
  • Subject is able to walk 5 steps with minimal assistance (stabilization of one arm or use of cane/walker).
  • Subject has an identified, reliable, study partner (e.g., caregiver, family member, social worker, or friend).

Exclusion Criteria:

  • Subjects who weigh less than 44 kg (97 lbs) at screening.
  • MMSE score less than 15 at screening.
  • Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI).
  • Subject resides at a skilled nursing or dementia care facility, or admission to such a facility is planned during the study period.
  • Evidence of any clinically significant neurological disorder other than PSP.
  • The subject has a history of or currently has schizophrenia, schizoaffective disorder or bipolar disorder according to DSM-V or ICD-10 criteria.
  • Subject has had a significant illness or infection requiring medical intervention in the past 30 days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02985879

Contact: ABBVIE CALL CENTER 847.283.8955 abbvieclinicaltrials@abbvie.com

  Show 50 Study Locations
Sponsors and Collaborators
Study Director: AbbVie Inc. AbbVie

Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT02985879     History of Changes
Other Study ID Numbers: M15-562
2016-001635-12 ( EudraCT Number )
First Posted: December 7, 2016    Key Record Dates
Last Update Posted: March 7, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by AbbVie:
Steele-Richardson-Olszewski syndrome

Additional relevant MeSH terms:
Supranuclear Palsy, Progressive
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Ocular Motility Disorders
Cranial Nerve Diseases
Neurodegenerative Diseases
Eye Diseases